{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T07:41:21Z","timestamp":1768722081870,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,4,28]],"date-time":"2013-04-28T00:00:00Z","timestamp":1367107200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s11906-013-0343-6","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T09:07:59Z","timestamp":1367399279000},"page":"182-189","source":"Crossref","is-referenced-by-count":29,"title":["Pharmacologic Treatment Options for Obesity: What Is Old Is New Again"],"prefix":"10.1007","volume":"15","author":[{"given":"Donna H.","family":"Ryan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Bray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,28]]},"reference":[{"issue":"6","key":"343_CR1","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/dc07-0048","volume":"30","author":"X Pi-Sunyer","year":"2007","unstructured":"Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care. 2007;30(6):1374\u201383.","journal-title":"Diabetes Care"},{"issue":"17","key":"343_CR2","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/archinternmed.2010.334","volume":"170","author":"RR Wing","year":"2010","unstructured":"Look AHEAD Research Group, Wing RR, et al. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566\u201375.","journal-title":"Arch Intern Med"},{"issue":"17","key":"343_CR3","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/archinternmed.2009.266","volume":"169","author":"GD Foster","year":"2009","unstructured":"Foster GD, Borradaile KE, Sanders MH, Millman R, Zammit G, Newman AB, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD Study. Arch Intern Med. 2009;169(17):1619\u201326.","journal-title":"Arch Intern Med"},{"issue":"3","key":"343_CR4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.juro.2011.10.139","volume":"187","author":"S Phelan","year":"2012","unstructured":"Phelan S, Kanaya A, Subak L, Hogan P, Espeland MA, Wing RR, et al. Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial. J Urol. 2012;187(3):939\u201344.","journal-title":"J Urol"},{"issue":"8","key":"343_CR5","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00125-010-1765-1","volume":"53","author":"RR Rubin","year":"2010","unstructured":"Rubin RR, Gaussoin SA, Peyrot M, DiLillo V, Miller K, Wadden TA, et al. Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia. 2010;53(8):1581\u20139.","journal-title":"Diabetologia"},{"issue":"13","key":"343_CR6","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa1110294","volume":"366","author":"J Rejeski","year":"2012","unstructured":"Rejeski J, Ip E, Bertoni A, Bray G, Evans G, Gregg E, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med. 2012;366(13):1209\u201317.","journal-title":"N Engl J Med"},{"issue":"6","key":"343_CR7","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2337\/dc09-2090","volume":"33","author":"JB Redmon","year":"2010","unstructured":"Redmon JB, Bertoni AG, Connelly S, Feeney PA, Glasser SP, Glick H, et al. Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care. 2010;33(6):1153\u20138.","journal-title":"Diabetes Care"},{"key":"343_CR8","unstructured":"Decision Memo for Intensive Behavioral Therapy for Obesity (CAG-00423\u00a0N). http:\/\/www.cms.gov\/medicare-coverage-database\/details\/nca-decision-memo.aspx?&NcaName=Intensive%20Behavioral%20Therapy%20for%20Obesity&bc=ACAAAAAAIAAA&NCAId=253 ."},{"key":"343_CR9","author":"L Sj\u00f6str\u00f6m","year":"2012","unstructured":"Sj\u00f6str\u00f6m L. Review of the key results from the Swedish Obese Subjects (SOS) trial: a prospective controlled intervention study of bariatric surgery. J Int Med. 2012. doi: 10.1111\/joim.12012 [Epub ahead of print].","journal-title":"J Int Med"},{"key":"343_CR10","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMoa1200225","volume":"366","author":"PR Schauer","year":"2012","unstructured":"Schauer PR, Kashyap SR, Wolski K, Brethauer SG, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567\u201376.","journal-title":"N Engl J Med"},{"key":"343_CR11","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1200111","volume":"366","author":"G Mingrone","year":"2012","unstructured":"Mingrone G, Panunzi S, DeGaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577\u201385.","journal-title":"N Engl J Med"},{"key":"343_CR12","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2337\/dc11-2289","volume":"35","author":"RV Cohen","year":"2012","unstructured":"Cohen RV, Pnheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420\u20138.","journal-title":"Diabetes Care"},{"key":"343_CR13","doi-asserted-by":"crossref","unstructured":"Bray GA. Do we need drugs to treat the patient with obesity? Obesity. 2013 (in press).","DOI":"10.1002\/oby.20394"},{"issue":"2","key":"343_CR14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"\u2022 Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20(2):330\u201342. This was one of the two pivotal Phase III clinical trials that underpinned the approval of phentermine\/topiramte (extended release) by the U.S. Food and Drug Administration.","journal-title":"Obesity"},{"issue":"9774","key":"343_CR15","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"\u2022 Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341\u201352. This was the other one of the two pivotal Phase III clinical trials that underpinned the approval of phentermine\/topiramate (extended release) by the U.S. Food and Drug Administration.","journal-title":"Lancet"},{"key":"343_CR16","unstructured":"FDA briefing information: meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. 2012. ( http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM292315.pdf )."},{"key":"343_CR17","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMp1211277","volume":"367","author":"E Colman","year":"2012","unstructured":"\u2022\u2022 Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA\u2019s assessment of two drugs for chronic weight management. N Engl J Med. 2012;367:1577\u20139. In this paper, Colman and colleagues provide comparative data on the weight losses for the two drugs that received U.S. Food and Drug Administration approval \u2013 lorcaserin and phentermine\/topiramate (extended release).","journal-title":"N Engl J Med"},{"key":"343_CR18","volume-title":"The LEARN manual for weight management","author":"KD Brownell","year":"2000","unstructured":"Brownell KD. The LEARN manual for weight management. Dallas: American Health Publishing Co; 2000."},{"key":"343_CR19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"\u2022\u2022 Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297\u2013308. This paper describes the two-year trial extending the treatment for people who completed the study described in # 15. It provides the two-year weight loss data showing that both the recommended dose and the top dose were associated with maintenance of almost all of their initial weight loss up to 2\u00a0years. In addition, there were significant improvements in almost all of the cardiometabolic risk factors.","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"343_CR20","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.5665\/sleep.2204","volume":"35","author":"DH Winslow","year":"2012","unstructured":"Winslow DH, Bowden CH, DiDonato KP, McCullough PA. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine\/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep. 2012;35(11):1529\u201339.","journal-title":"Sleep"},{"key":"343_CR21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/14740330902931524","volume":"8","author":"RB Rothman","year":"2009","unstructured":"Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf. 2009;8:317\u201329.","journal-title":"Expert Opin Drug Saf"},{"key":"343_CR22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200767010-00004","volume":"67","author":"JC Halford","year":"2007","unstructured":"Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs. 2007;67:27\u201355.","journal-title":"Drugs"},{"key":"343_CR23","unstructured":"FDA briefing information: meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. 2012. ( http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM303198.pdf )."},{"key":"343_CR24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","volume":"363","author":"SR Smith","year":"2010","unstructured":"\u2022\u2022 Smith SR, Weissman NJ, Anderson CM Sanchez M, Chuang E, Stubbe S, Bays H, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245\u201356. This is one of the pivotal Phase III studies of lorcaserin that was used to obtain approval from the U.S. FDA.","journal-title":"N Engl J Med"},{"key":"343_CR25","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","volume":"96","author":"MC Fidler","year":"2011","unstructured":"\u2022 Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. was significantly greater than with placebo. J Clin Endocrinol Metab. 2011;96:3067\u201377. This is another pivotal Phase III studies of lorcaserin that was used to obtain approval from the U.S. FDA.","journal-title":"J Clin Endocrinol Metab"},{"key":"343_CR26","doi-asserted-by":"crossref","unstructured":"\u2022 O\u2019Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Raether B, Anderson CM, Shanahan WR. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426\u201336. doi: 10.1038\/oby.2012.66 . Epub 2012 Mar 16. This randomized clinical trial shows that lorcaserin significantly reduced body weight and improved cardiometabolic risk factors in patients with diabetes mellitus.","DOI":"10.1038\/oby.2012.66"},{"key":"343_CR27","unstructured":"Contrave (Naltrexone SR\/Bupropion SR Combination) Advisory Committee Briefing Document. NDA 200063. Endocrinologic and Metabolic Drugs Advisory Committee Meeting, December 7, 2010."},{"key":"343_CR28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicenter, randomised, double\u2009=\u2009blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595\u2013605.","journal-title":"Lancet"},{"key":"343_CR29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O\u2019Neil PM, et al. Weight loss with naltrexoneSR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19:110\u201320.","journal-title":"Obesity"},{"key":"343_CR30","unstructured":"http:\/\/www.accessdata.fda.gov\/drugsaftfda_docs\/label\/2011\/202088s001lbl.pdf ."},{"key":"343_CR31","unstructured":"VI-0521 (QNEXA\u00ae) Advisory Committee Briefing Document. NDA 022580. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 2010. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM292317.pdf . Accessed 15 March 2012."},{"key":"343_CR32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000304921","volume":"3","author":"D Ryan","year":"2010","unstructured":"Ryan D, Peterson C, Troupin B, Najarian T, Tam P, Day W. Weight loss at 6\u00a0months with VI-0521 (PHEN\/TPM combination) treatment. Obes Facts. 2010;3:139\u201346.","journal-title":"Obes Facts"},{"key":"343_CR33","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1463-1326.2010.01242.x","volume":"12","author":"JG Kang","year":"2010","unstructured":"Kang JG, Park C-Y, Kang JH, Park Y-W, Park SW. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes Obesity Metab. 2010;12:876\u201382.","journal-title":"Diabetes Obesity Metab"},{"issue":"10","key":"343_CR34","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/0091270009341651","volume":"49","author":"C Addy","year":"2009","unstructured":"Addy C, Rosko JP, Li S, Li H, Maes A, Johnson-Levonas AO, et al. Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist. J Clin Pharmacol. 2009;49(10):1228\u201338.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"343_CR35","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3349\/ymj.2006.47.5.614","volume":"47","author":"KK Kim","year":"2006","unstructured":"Kim KK, Cho H-J, Kang J-C, Youn B-B, Lee K-R. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J. 2006;47(5):614\u201325.","journal-title":"Yonsei Med J"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-013-0343-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-013-0343-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-013-0343-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:14:31Z","timestamp":1559434471000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-013-0343-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,28]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["343"],"URL":"https:\/\/doi.org\/10.1007\/s11906-013-0343-6","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,28]]}}}